Grant: Idea to Innovation
McGill University
$122,500.00
Electronic microfluidic systems
FY 2007-08
Summary
Miniaturization, integration and parallelization has driven the (micro)electronic revolution and has started to bear strongly on the life sciences, and already revolutionized gene expression profiling with DNA microarray chips containing close to a million of different DNA probes. Cells have recently become an important focus of the drug discovery processes following the increasing rate of failures of drugs in late clinical trials or subsequent to market introduction. High throughput cell assays are now performed automatically in 96 or 384 well plates, but are complex to perform and expensive because expensive liquid handling robots and large amounts of chemicals are necessary.There are no intrinsic biological barriers to the further miniaturization and parallelization of cellular assays within microfluidic systems, except for the lack of a microfluidic technology that supports miniaturization, integration, parallelization and automation on a large scale. Here, we propose a new microfluidic chip architecture that can be interfaced directly with microelectronic chips and that is therefore scalable We have invented a novel control architecture and developed a new electrostatic valves that can be closed by applying a voltage, and therefore directly controlled using electronic chips. Thus, using a computer, complex fluidic operations can be programmed and using a microelectronic chip the electrostatic valves in the microfluidic chip actuated accordingly. This concept hinges on the large scale integration of microelectronic chips and will allow accelerating the integration and parallelization of microfluidics.Electronic microfluidic systems will be characterized by an extraordinary versatility and ideally suited for performing complex experimental protocols in parallel with high throughput while economizing reagents and reducing costs. We believe that such electronic microfluidic chips could transform high cell biology--specifically high throughput cell assay--and medicine akin to the way that DNA chips and high throughput sequencers have transformed, and are still transforming, them.
Program
Idea to Innovation
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
350240-2007
Name nom
Juncker, David
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2007
Award amount
122500
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
7000
Research subject group en
Other studies in natural sciences and engineering
Research subject group fr
Autres études en sciences naturelles et en génie
Research subject en
Other studies in natural sciences and engineering
Research subject fr
Autres études en sciences naturelles et en génie
Partie
1
Nb partie
1
Application title
Electronic microfluidic systems
Keyword
NA
Application summary
Miniaturization, integration and parallelization has driven the (micro)electronic revolution and has started to bear strongly on the life sciences, and already revolutionized gene expression profiling with DNA microarray chips containing close to a million of different DNA probes. Cells have recently become an important focus of the drug discovery processes following the increasing rate of failures of drugs in late clinical trials or subsequent to market introduction. High throughput cell assays are now performed automatically in 96 or 384 well plates, but are complex to perform and expensive because expensive liquid handling robots and large amounts of chemicals are necessary.There are no intrinsic biological barriers to the further miniaturization and parallelization of cellular assays within microfluidic systems, except for the lack of a microfluidic technology that supports miniaturization, integration, parallelization and automation on a large scale. Here, we propose a new microfluidic chip architecture that can be interfaced directly with microelectronic chips and that is therefore scalable We have invented a novel control architecture and developed a new electrostatic valves that can be closed by applying a voltage, and therefore directly controlled using electronic chips. Thus, using a computer, complex fluidic operations can be programmed and using a microelectronic chip the electrostatic valves in the microfluidic chip actuated accordingly. This concept hinges on the large scale integration of microelectronic chips and will allow accelerating the integration and parallelization of microfluidics.Electronic microfluidic systems will be characterized by an extraordinary versatility and ideally suited for performing complex experimental protocols in parallel with high throughput while economizing reagents and reducing costs. We believe that such electronic microfluidic chips could transform high cell biology--specifically high throughput cell assay--and medicine akin to the way that DNA chips and high throughput sequencers have transformed, and are still transforming, them.